{"id":30673,"date":"2016-10-01T09:10:36","date_gmt":"2016-10-01T09:10:36","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=30673"},"modified":"2016-10-03T17:17:53","modified_gmt":"2016-10-03T17:17:53","slug":"brazil-to-start-using-dolutegravir-first-line-in-its-national-programme","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/30673","title":{"rendered":"Brazil to start using dolutegravir first-line in its national programme"},"content":{"rendered":"<p><strong>Polly Clayden, HIV i-Base<\/strong><\/p>\n<p><strong>Brazil will begin to use dolutegravir in its national programme early next year. The Ministry of Health has negotiated a 70% price reduction with ViiV Healthcare.<\/strong><\/p>\n<p>On 28 September, the Brazilian Ministry of Health announced that it expects to be treating about 80,000 new first-line patients with dolutegravir plus 20,000 who switch from efavirenz due to side effects by the end of 2017.<\/p>\n<p>Brazil has planned a phased process that will exclude pregnant women and people receiving co-treatment for TB. The agreed price is around US$ 500 per person per year for dolutegravir &#8211; and the country has bought 40 million tablets. &#8220;We are offering this treatment without budgetary impact,&#8221; said the director of the ministry Adele Benzaken. (ie at no greater cost than efavirenz). Distribution will start in January 2017.<\/p>\n<h3>Comment<\/h3>\n<p><strong>This is very good news. At this price, the overall Brazilian HIV budget will not be affected. And this news should be a useful bargaining tool for other middle-income countries that will hopefully be able to negotiate similar price levels for dolutegravir.<\/strong><\/p>\n<p>Reference:<\/p>\n<p>Luiz G. Medicamento dolutegravir \u00e9 nova op\u00e7\u00e3o do SUS para pacientes com HIV. 28 September 2016.<br \/>\n<a href=\"http:\/\/g1.globo.com\/bemestar\/noticia\/2016\/09\/medicamento-dolutagravir-e-nova-opcao-do-sus-para-pacientes-com-hiv.html\">http:\/\/g1.globo.com\/bemestar\/noticia\/2016\/09\/medicamento-dolutagravir-e-nova-opcao-do-sus-para-pacientes-com-hiv.html<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Polly Clayden, HIV i-Base Brazil will begin to use dolutegravir in its national programme early next year. The Ministry of Health has negotiated a 70% price reduction with ViiV Healthcare. On 28 September, the Brazilian Ministry of Health announced that &hellip;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[38],"tags":[],"class_list":["post-30673","post","type-post","status-publish","format-standard","hentry","category-treatment-access"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/30673","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=30673"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/30673\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=30673"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=30673"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=30673"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}